These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Fludarabine monophosphate as salvage for refractory chronic lymphocytic leukaemia.
    Author: Pillay GS, Wood L, Jacobs P.
    Journal: S Afr Med J; 1996 Aug; 86(8):949-51. PubMed ID: 8823419.
    Abstract:
    OBJECTIVE: To assess the efficacy of the purine analogue fludarabine monophosphate (FAMP) as salvage therapy in patients at Groote Schuur Hospital with chronic lymphocytic leukaemia (CLL) refractory to standard therapy. DESIGN: Non-randomised trial. SETTING: Tertiary care, referral academic hospital. PATIENTS: Seven patients with B-lineage CLL, 4 in Rai stage IV and 1 each in stages A(I), A(II) and A(III), refractory to treatment with chlorambucil or cyclophosphamide, with or without whole-body irradiation. INTERVENTION: Intravenous FAMP at a dose of 25 mg/m2 daily for 5 days every 28 days. MAIN OUTCOME MEASURES: Partial remission, complete remission, stable disease or progressive disease. RESULTS: Two patients entered CR and 4 PR after a median of 8 courses of treatment (range 2 - 12). One patient died of Pneumocystis carinii pneumonia after 3 courses of therapy. The most common adverse effect of the treatment was myelosuppression, with the nadir of neutrophil counts being less than 0.5 x 10(9)/1 in 5 patients. Three developed infections and required hospitalisation while on therapy. CONCLUSION: FAMP is effective as a cytoreductive agent in patients with CLL refractory to alkylating agents, with or without whole-body irradiation.
    [Abstract] [Full Text] [Related] [New Search]